Ronda Duffy

Overview

EVP and Chief Operations Officer at Biocon Biologics, responsible for biosimilar supply reliability across manufacturing sites in Bangalore and Johor Bahru with a focus on inventory strategy and logistics. Ronda Duffy is EVP and COO of Biocon Biologics, having spent 29.5 years at Leo Pharma in Europe before retiring and joining Biocon in 2023; in April 2026, Biocon Biologics re-amalgamated into its parent company, adding GLP-1s, statins, and anti-rejection generics to her portfolio. Biosimilar supply planning is severely challenged by forecast volatility: Biocon's commercial team doubled their aflibercept US launch forecast one day before launch, while the company targets six months of market inventory at launch and contracts make rapid adjustment nearly impossible. (Segment 3 (10:00-15:00))